Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807114 | 0.84 | IDO1 (0.43) | AURKAMAPK14IDO1EGFRACP1 | |
| SCHEMBL19418577 | 0.82 | STK17A (0.35) | TAS2R14MAPTRAB9ASMN1; SMN2IDO1 | |
| SCHEMBL2806555 | 0.82 | IDO1 (0.41) | GAARAB9AIDO1EGFR | |
| SCHEMBL2811521 | 0.82 | PTGS2 (0.45) | PTGS2SLC22A12IDO1EGFR | |
| SCHEMBL674012 | 0.79 | CNR2 (0.41) | MAPK14GAAMAPTEPHX2 | |
| SCHEMBL185469 | 0.77 | MAOB (0.50) | ALDH1A1TDP1POLBL3MBTL1PTGS2 | |
| SCHEMBL19418575 | 0.77 | IDO1 (0.35) | AURKAMAPK14GAAIDO1 | |
| SCHEMBL185004 | 0.77 | EGFR (0.42) | ALDH1A1TDP1POLBL3MBTL1PTGS2 | |
| SCHEMBL185616 | 0.76 | LRRK2 (0.42) | ALDH1A1POLBAURKATAS2R14GAA | |
| SCHEMBL1921413 | 0.76 | ALDH1A1 (0.57) | ALDH1A1TDP1POLBL3MBTL1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539323-B3 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2539323-B3 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2539323-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2014-12-03 | — | — | EP | disclosed |
| EP-2539323-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2014-12-03 | — | — | EP | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| US-8372838-B2 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| CN-102414177-A | Compounds as bradykinin b1 antagonists | BOEHRINGER INGELHEIM INT | 2012-04-11 | — | — | CN | disclosed |
| EP-2401256-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011104203-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | ALDH1A1 3359/4885TDP1 3400/4885POLB 3734/4885 |
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | ALDH1A1 1000/4885TDP1 2237/4885POLB 3203/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | ALDH1A1 1000/4885TDP1 2237/4885POLB 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.